Social media

Cardiovascular outcomes trials (CVOTs) are essential for demonstrating clinical value and meeting regulatory expectations but they’re also complex and resource-intensive. On December 8-10, connect with ICON experts at CV...

Cardiovascular outcomes trials (CVOTs) are essential for demonstrating clinical value and meeting regulatory expectations but they’re also complex and resource-intensive. On December 8-10, connect with ICON experts at CV...

Early phase neurodegenerative trials require careful planning, a patient-first approach, and biomarker strategies that drive progress. Tune in to our recent ASCPT-hosted webinar, where we explored: - How to define target...

Early phase neurodegenerative trials require careful planning, a patient-first approach, and biomarker strategies that drive progress. Tune in to our recent ASCPT-hosted webinar, where we explored: - How to define target...

Site activation delays cost trials time and trust. ICON’s new whitepaper shows how human-centred strategies accelerate startup and improve site satisfaction. Download now: https://ow.ly/f5EO50XB6ZL

55% of sites report activation timelines of five months or longer. Our new whitepaper explores why, and how to fix it. Download now: https://ow.ly/j6RK50XB6ZW

Learn how to build a JCA dossier that supports both EU-wide assessments and national reimbursement needs. Download the whitepaper: https://ow.ly/2wWF50XgHL8 #ValueCommunication #HEOR #HTA #ICONInsights

Learn how to build a JCA dossier that supports both EU-wide assessments and national reimbursement needs. Download the whitepaper: https://ow.ly/2wWF50XgHL8 #ValueCommunication #HEOR #HTA #ICONInsights

Integrating advanced delivery systems, often accelerated by AI modelling, is a game-changer for biopharmaceutical success. In this article for BioPharm International, ICON’s Head of Regulatory CMC, Venkat Sunkara, MSc, M...

Want to know what’s missing in next-gen drug delivery? In this article for BioPharm International, ICON’s Head of Regulatory CMC, Venkat Sunkara, outlines current product development trends happening in the world of bio...

How to navigate EU MAA Regulations and Registration. For Chinese pharma and biotech companies looking to expand into the European Union’s market of over 450 million people, the first step is to understand the significant...

How to navigate EU MAA Regulations and Registration Regulatory legislation in China differs substantially from that of the European Union. For Chinese biotech companies looking to enter this market it is critical to ass...